Supporting UK healthcare professionals with an
alternative treatment option for patients at risk
EURneffy® nasal adrenaline spray for anaphylaxis
*this is not the actual size of the product
The systemic impact of anaphylaxis
Anaphylaxis is a serious systemic hypersensitivity reaction that is usually rapid in onset and may be life threatening. It can involve the airway, breathing and/or circulation, and may progress quickly without prompt treatment.1
EURneffy® features
Needle-free
The first and only approved needle-free and ready-to-use nasal adrenaline spray (NAS) for anaphylaxis treatment.2
Temperature stable
No special storage required. If accidentally frozen, thaw for one hour; shelf life unaffected.2
Long shelf life
30-month shelf life from date of production.2
Ready-to-use
Place in nostril and press without priming.2
Two-dose pack
EURneffy® is available in a pack of two single-dose nasal sprays. Patients should always carry two nasal sprays in case a second dose is needed.2
Anaphylaxis treatment update
More than 600 UK HCPs joined Prof George du Toit and Dr Shelley Dua for this live webinar on anaphylaxis management and adrenaline treatment options.
EURneffy® clinical overview
See the clinical data, prescribing information and an overview of how EURneffy® works.
Adrenaline for anaphylaxis
Adrenaline should be used without delay at the first signs of a severe allergic reaction or when anaphylaxis is suspected.1 It acts on adrenergic receptors to:
- counter vasodilation
- reduce airway swelling
- relieve bronchospasm
- help restore blood pressure and blood flow to vital organs.1
What is EURneffy®?
EURneffy® 2 mg nasal adrenaline spray (NAS) is indicated for adults and children weighing ≥30 kg for the emergency treatment of severe allergic reactions (anaphylaxis) due to2:
- insect stings or bites
- foods, medicinal products and other allergens
- idiopathic or exercise-induced anaphylaxis2
Using EURneffy® in an emergency
EURneffy® is a ready-to-use, single-dose nasal adrenaline spray for use at the first signs of a severe allergic reaction (anaphylaxis).2
If symptoms don’t improve or worsen after 5 minutes, a second dose should be used. Patients should always carry two nasal (adrenaline) sprays and call 999 immediately after use.2
Patient brochure
The patient brochure includes:
- how to recognise a severe allergic reaction
- when to use EURneffy®
- how to use the device
- checking expiry dates
How to use EURneffy®
EURneffy® materials for you and your patients
Patient consultation guide
A practical guide to support effective patient conversations about EURneffy®
FAQ
Foods, insect stings or bites, and medicinal products are among the most common triggers. Some patients experience idiopathic or exercise-induced anaphylaxis. Symptoms can develop rapidly and may affect the airways, skin, gastrointestinal tract and cardiovascular system.1
Adrenaline should be used without delay at the first signs of a severe allergic reaction or when anaphylaxis is suspected. Severe allergic reactions can progress rapidly, so prompt treatment is important.¹ Delays in treatment have been associated with poorer outcomes.1
EURneffy® delivers adrenaline intranasally2, while auto-injectors deliver adrenaline by intramuscular injection4.
Patient needs can change, particularly in children and young people. Reviewing treatment helps ensure the dose remains appropriate as weight and age change and may not always align with current prescribing.3
EURneffy® is for immediate use in a suspected anaphylactic reaction. It delivers a single dose of adrenaline as a ready-to-use nasal spray.2
Place the tip of EURneffy® into one nostril and press the plunger. No priming is required. EURneffy® delivers a single dose of adrenaline as a nasal spray.2
Patients should always carry two EURneffy® nasal sprays. A second dose may be needed if symptoms persist or do not improve after the first dose.2
No. EURneffy® requires no special storage conditions. If the device freezes, thaw it for 1 hour before use. This does not affect the shelf life.2
EURneffy® has a 30-month shelf life from the date of production.2
Contact your local ALK Pro representative for clinical data, training materials and practice support.
If you’d like to speak to a representative
Indication
EURneffy® is indicated for the emergency treatment of severe allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis, in adults and children weighing ≥30 kg.2
1. Resuscitation Council UK. Emergency treatment of anaphylaxis: Guidelines for healthcare providers. 2021.
2. EURneffy® Summary of Product Characteristics. 2025.
3. Michaelis LJ, et al. Clinical & Experimental Allergy. 2025.
4. EpiPen® Adrenaline (Epinephrine) Auto-Injector. Summary of Product Characteristics. 2025.
May 2026
GB-EURn-2600069